Healing Touch During Chemotherapy Infusions for Women With Breast Cancer
NCT ID: NCT00533663
Last Updated: 2022-06-23
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
32 participants
INTERVENTIONAL
2007-04-30
2010-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Healing Touch and Health-Related Quality of Life in Women With Breast Cancer Receiving Radiation Therapy
NCT00612443
Evaluation of Effectiveness of Acupuncture on Quality of Life in Patients With Breast Cancer Receiving Chemotherapy
NCT01727362
Healing Touch in Treating Fatigue in Women Undergoing Radiation Therapy for Breast Cancer
NCT00574145
A Pilot Study of Acupuncture for Chemotherapy-induced Peripheral Neuropathy in Breast Cancer Patients
NCT02129686
Acupuncture for Hot Flashes in Hormone Receptor-Positive Breast Cancer, a Randomized Controlled Trial
NCT03783546
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
FACTORIAL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Standard Care + Healing Touch (HT)
A a gentle, non-invasive form of energy-balancing work that promotes relaxation and can help manage the side effects of chemotherapy. It occurs every other week (during their infusion).
Healing Touch
every other week (during their infusion)
Standard care
Adriamycin, cyclophosphamide, and paclitaxel administered as standard of care
Standard Care + Guided relaxation
Guided relaxation every other week (during their infusion).
Standard care
Adriamycin, cyclophosphamide, and paclitaxel administered as standard of care
guided relaxation
standard care only
Standard care
Standard care
Adriamycin, cyclophosphamide, and paclitaxel administered as standard of care
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Healing Touch
every other week (during their infusion)
Standard care
Adriamycin, cyclophosphamide, and paclitaxel administered as standard of care
guided relaxation
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Concurrent enrollment on a treatment protocol of 8 weeks of adriamycin + cyclophosphamide given every other week followed by 8 weeks of paclitaxel given every other week
* ECOG Performance Status: 0 to 2
* Speak and read English
Exclusion Criteria
18 Years
70 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Stanford University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Kathy Turner, RN, NP
Role: PRINCIPAL_INVESTIGATOR
Stanford University
Alice "Ellie" Guardino, RN, NP
Role: PRINCIPAL_INVESTIGATOR
Stanford University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Stanford University School of Medicine
Stanford, California, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
BRSADJ0007
Identifier Type: OTHER
Identifier Source: secondary_id
IRB-07696
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.